HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
HJV
hemojuvelin BMP co-receptor
Chromosome 1 Β· 1q21.1
NCBI Gene: 148738Ensembl: ENSG00000168509.21HGNC: HGNC:4887UniProt: A8K466
94PubMed Papers
21Diseases
0Drugs
78Pathogenic Variants
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
multicellular organismal-level iron ion homeostasisBMP receptor activitysignaling receptor bindingprotein bindinghemochromatosis type 2Ahemochromatosis type 2hereditary hemochromatosis type 1isolated hyperferritinemia
✦AI Summary

HJV (hemojuvelin) functions as a bone morphogenetic protein (BMP) coreceptor that enhances BMP signaling to regulate hepcidin (HAMP) expression and maintain iron homeostasis 1. As a signaling molecule expressed in the liver, HJV senses iron accumulation and participates in the complex regulatory pathways that control hepcidin, the iron regulatory hormone 2. Hepcidin, in turn, regulates ferroportin activity to control iron entry into the bloodstream and prevent systemic iron overload 3. Mutations in HJV cause juvenile hemochromatosis type 2A (JH2A), a severe autosomal recessive disorder characterized by rapid, multi-organ iron accumulation 4. Unlike the common HFE-associated hemochromatosis, HJV mutations produce early-onset disease affecting both sexes equally, with iron deposition in cardiac, hepatic, endocrine, and other parenchymal tissues 4. Though HJV mutations are rare, they are more central to iron homeostasis than HFE and represent important models for understanding iron trafficking mechanisms 5. Clinical recognition of HJV-related hemochromatosis requires genetic testing and is critical for early intervention with aggressive iron chelation therapy to prevent organ dysfunction and potentially avoid transplantation 4.

Sources cited
1
HJV acts as a BMP coreceptor that enhances BMP signaling to regulate hepcidin expression and iron homeostasis
PMID: 18976966
2
HJV is a signaling molecule that senses iron accumulation and regulates hepcidin biology
PMID: 20542038
3
Hepcidin regulates ferroportin to control iron entry into blood; HJV mutations cause non-HFE hemochromatosis
PMID: 29620054
4
HJV mutations cause juvenile hemochromatosis type 2A with severe, early-onset multi-organ iron accumulation affecting both sexes
PMID: 33861982
5
HJV gene products are more central to human iron homeostasis than HFE and advance understanding of iron trafficking
PMID: 16315138
Disease Associationsβ“˜21
hemochromatosis type 2AOpen Targets
0.81Strong
hemochromatosis type 2Open Targets
0.53Moderate
hereditary hemochromatosis type 1Open Targets
0.42Moderate
isolated hyperferritinemiaOpen Targets
0.09Suggestive
FTH1-related iron overloadOpen Targets
0.09Suggestive
hemochromatosis type 5Open Targets
0.09Suggestive
microcytic anemia with liver iron overloadOpen Targets
0.08Suggestive
hepatocellular carcinomaOpen Targets
0.08Suggestive
Adult-onset autosomal recessive sideroblastic anemiaOpen Targets
0.08Suggestive
GRACILE syndromeOpen Targets
0.07Suggestive
hereditary hyperferritinemia with congenital cataractsOpen Targets
0.06Suggestive
severe congenital hypochromic anemia with ringed sideroblastsOpen Targets
0.06Suggestive
congenital bile acid synthesis defect 5Open Targets
0.06Suggestive
Congenital bile acid synthesis defect type 1Open Targets
0.06Suggestive
hemochromatosis type 2BOpen Targets
0.06Suggestive
neonatal hemochromatosisOpen Targets
0.06Suggestive
sideroblastic anemia 3Open Targets
0.06Suggestive
zinc deficiency, transient neonatalOpen Targets
0.06Suggestive
type 2 diabetes mellitusOpen Targets
0.06Suggestive
MEDNIK syndromeOpen Targets
0.06Suggestive
Hemochromatosis 2AUniProt
Pathogenic Variants78
NM_213653.4(HJV):c.959G>T (p.Gly320Val)Pathogenic
Hemochromatosis type 1|Hemochromatosis type 2A|not provided|Juvenile hemochromatosis
β˜…β˜…β˜†β˜†2026β†’ Residue 320
NM_213653.4(HJV):c.703del (p.Val235fs)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2026β†’ Residue 235
NM_213653.4(HJV):c.445del (p.Asp149fs)Pathogenic
Hemochromatosis type 2A|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 149
NM_213653.4(HJV):c.59dup (p.Ser21fs)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 21
NM_213653.4(HJV):c.769C>T (p.Arg257Ter)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 257
NM_213653.4(HJV):c.976C>T (p.Arg326Ter)Pathogenic
Hemochromatosis type 2A|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 326
NM_213653.4(HJV):c.81del (p.Leu28fs)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 28
NM_213653.4(HJV):c.302T>C (p.Leu101Pro)Pathogenic
Hemochromatosis type 2A|not provided|HJV-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 101
NM_213653.4(HJV):c.238T>C (p.Cys80Arg)Pathogenic
Hemochromatosis type 2A|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 80
NM_213653.4(HJV):c.1006G>T (p.Gly336Ter)Pathogenic
Hemochromatosis type 2A|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 336
NM_213653.4(HJV):c.220del (p.Val74fs)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 74
NM_213653.4(HJV):c.516C>G (p.Asp172Glu)Likely pathogenic
Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 172
NM_213653.4(HJV):c.399del (p.Ala134fs)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 134
NM_213653.4(HJV):c.1153C>T (p.Arg385Ter)Likely pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 385
NM_213653.4(HJV):c.962_963delinsAA (p.Cys321Ter)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 321
NM_213653.4(HJV):c.265T>C (p.Cys89Arg)Likely pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 89
NM_213653.4(HJV):c.196G>T (p.Gly66Ter)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 66
NM_213653.4(HJV):c.842T>C (p.Ile281Thr)Pathogenic
Hemochromatosis type 2A|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 281
NM_213653.4(HJV):c.765_766del (p.Asp256fs)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 256
NM_213653.4(HJV):c.295G>A (p.Gly99Arg)Pathogenic
not provided|Hemochromatosis type 2A
β˜…β˜…β˜†β˜†2025β†’ Residue 99
View on ClinVar β†—
Related Genes
SMAD4Protein interaction93%GDF5Protein interaction92%ACVR1Protein interaction91%ACVRL1Protein interaction91%BMP2Protein interaction91%BMP4Protein interaction91%
Tissue Expression6 tissues
Liver
100%
Heart
43%
Lung
0%
Brain
0%
Ovary
0%
Bone Marrow
0%
Gene Interaction Network
Click a node to explore
HJVSMAD4GDF5ACVR1ACVRL1BMP2BMP4
PROTEIN STRUCTURE
Preparing viewer…
PDB4UI1 Β· 2.35 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.15LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.81 [0.58–1.15]
RankingsWhere HJV stands among ~20K protein-coding genes
  • #5,087of 20,598
    Most Researched94 Β· top quartile
  • #951of 5,498
    Most Pathogenic Variants78 Β· top quartile
  • #11,947of 17,882
    Most Constrained (LOEUF)1.15
Genes detectedHJV
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Haemochromatosis.
PMID: 29620054
Nat Rev Dis Primers Β· 2018
1.00
2
Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.
PMID: 20542038
Gastroenterology Β· 2010
0.90
3
Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
PMID: 35780807
Lancet Gastroenterol Hepatol Β· 2022
0.80
4
Juvenile haemochromatosis.
PMID: 33861982
Lancet Child Adolesc Health Β· 2021
0.70
5
Encephalitic alphaviruses.
PMID: 19775836
Vet Microbiol Β· 2010
0.60